Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35135718)
Watch
English
Benefits and adverse effects of endocrine therapy
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
title
Benefits and adverse effects of endocrine therapy
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
author
Marco Colleoni
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
author name string
A Giobbie-Hurder
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
publication date
1 October 2010
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
published in
Annals of Oncology
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
volume
21 Suppl 7
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
page(s)
vii107-11
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
cites work
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Meta-analysis of vascular and neoplastic events associated with tamoxifen
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Osteopenia and osteoporosis in women with breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Aromatase inhibitors in breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Has tamoxifen had its day?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
28 July 2018
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Acceptance of adjuvant therapy and quality of life issues
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Very young women (<35 years) with operable breast cancer: features of disease at presentation.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Adjuvant therapy for very young women with breast cancer: need for tailored treatments
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146255
retrieved
27 September 2018
Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20943602
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20943602
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Age as prognostic factor in premenopausal breast carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20943602
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20943602
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20943602
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20943602
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20943602
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1093/ANNONC/MDQ281
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
PMC publication ID
3146255
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
PubMed publication ID
20943602
1 reference
stated in
Europe PubMed Central
PMC publication ID
3146255
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943602%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 February 2020
ResearchGate publication ID
47414522
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit